PENNY MAKABENTA: Open Payments
NPI 1245439157 · FULLERTON, CA. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$449 in 20 payments from 8 companies in 2025. Trend: 2023 $150 · 2024 $427 · 2025 $449
Food & beverage: $449
| Company | Payments | Amount |
|---|---|---|
| Novo Nordisk Inc | 12 | $236 |
| Lilly USA, LLC | 2 | $64 |
| MAYNE PHARMA COMMERCIAL LLC | 1 | $32 |
| GlaxoSmithKline, LLC. | 1 | $26 |
| ALK-Abello, Inc | 1 | $24 |
| Amgen Inc. | 1 | $23 |
| PFIZER INC. | 1 | $22 |
| Intra-Sana Laboratories | 1 | $21 |
Products named: Wegovy, MOUNJARO, SHINGRIX, Rybelsus, NEFFY, OTEZLA, NURTEC ODT, RELTONE 200 MG.
Industry payments across CA — which companies pay providers there.
